Upgrade to SI Premium - Free Trial

Taysha Gene Therapies (TSHA)

4.01 -0.11 (2.67%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 2, 2026 8:00 AM - StreetInsider Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting October 1, 2026 8:00 AM - StreetInsider Wolfe Research Starts Taysha Gene Therapies (TSHA) at Outperform September 17, 2026 5:03 AM - StreetInsider Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 4, 2026 8:00 AM - StreetInsider Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P. August 14, 2026 4:50 PM - SEC Filing Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: MORGAN STANLEY August 13, 2026 5:38 PM - SEC Filing Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c August 11, 2026 4:19 PM - StreetInsider Form 10-Q Taysha Gene Therapies, For: Jun 30 August 11, 2026 4:08 PM - SEC Filing Form 8-K Taysha Gene Therapies, For: Aug 11 August 11, 2026 4:06 PM - SEC Filing Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update August 11, 2026 4:00 PM - StreetInsider Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 7, 2026 8:00 AM - StreetInsider Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 August 4, 2026 4:00 PM - StreetInsider Taysha and Catalent sign commercial manufacturing deal for Rett therapy August 3, 2026 8:00 AM - StreetInsider Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome August 3, 2026 8:00 AM - StreetInsider Full Article List